HC Wainwright Lifts Earnings Estimates for Cabaletta Bio

Key Points

• HC Wainwright raised Cabaletta Bio’s FY2026 EPS estimate to a loss of $1.26 per share from a loss of $1.35, and reiterated its Buy rating and $16 price target.
• Cabaletta Bio reported a quarterly loss of $0.28 per share, beating analysts’ consensus estimate of a $0.32 loss by $0.04.
• Analyst views are mixed: MarketBeat’s consensus rating is Moderate Buy, with an average price target of $14.33; individual ratings range from Strong Buy to Sell.

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Cabaletta Bio in a research note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.26) per share for the year, up from their prior estimate of ($1.35). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Cabaletta Bio's current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Cabaletta Bio's Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.53) EPS.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04.

Several other brokerages have also issued reports on CABA. William Blair upgraded Cabaletta Bio to a "strong-buy" rating in a report on Wednesday, September 23rd. Wells Fargo & Company dropped their price objective on Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Friday, August 14th. TD Cowen raised shares of Cabaletta Bio to a "strong-buy" rating in a research report on Monday, August 24th. Wall Street Zen raised shares of Cabaletta Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cabaletta Bio currently has an average rating of "Moderate Buy" and a consensus price target of $14.33.

Cabaletta Bio Stock Up 15.4%

Shares of CABA stock opened at $1.50 on Tuesday. Cabaletta Bio has a fifty-two week low of $1.18 and a fifty-two week high of $4.23. The stock's 50-day moving average is $2.09 and its two-hundred day moving average is $2.82.

Hedge Funds Weigh In On Cabaletta Bio

Several hedge funds have recently bought and sold shares of the business. StoneX Group Inc. acquired a new stake in shares of Cabaletta Bio in the third quarter worth about $26,000. Simplify Asset Management Inc. bought a new stake in shares of Cabaletta Bio during the 3rd quarter worth about $1,068,000. Nisa Investment Advisors LLC boosted its stake in shares of Cabaletta Bio by 3,976.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 33,061 shares of the company's stock worth $63,000 after acquiring an additional 32,250 shares in the last quarter. Opaleye Management Inc. increased its holdings in shares of Cabaletta Bio by 180.0% during the 2nd quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company's stock valued at $12,016,000 after acquiring an additional 2,483,800 shares during the last quarter. Finally, WINTON GROUP Ltd increased its holdings in shares of Cabaletta Bio by 76.5% during the 2nd quarter. WINTON GROUP Ltd now owns 27,000 shares of the company's stock valued at $84,000 after acquiring an additional 11,700 shares during the last quarter.

More Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2029, reflecting smaller expected losses, and reiterated its Buy rating with a $16 price target. For example, its FY2027 loss estimate improved to $1.02 per share from $1.29. Cabaletta Bio analyst coverage
• Positive Sentiment: New rese-cel Phase 1/2 results were encouraging: all six dermatomyositis patients maintained moderate-to-major responses without immunomodulators through one year, with most also off steroids. This may strengthen the case for the therapy, though the data are early-stage. Rese-cel Phase 1/2 data
• Neutral Sentiment: Citigroup cut its price target to $8 but maintained a Buy rating, leaving a positive recommendation while signaling a more cautious valuation view. Citigroup price-target update
• Negative Sentiment: A separate analyst reduced its FY2030 EPS estimate, a counterpoint to HC Wainwright’s improved forecasts. FY2030 EPS estimate change

Cabaletta Bio Company Profile

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company's approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.